Literature DB >> 20962279

Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage.

Pramod K Mistry1, Jun Liu, Mei Yang, Timothy Nottoli, James McGrath, Dhanpat Jain, Kate Zhang, Joan Keutzer, Wei-Lien Chuang, Wei-Lein Chuang, Wajahat Z Mehal, Hongyu Zhao, Aiping Lin, Shrikant Mane, Xuan Liu, Yuan Z Peng, Jian H Li, Manasi Agrawal, Ling-Ling Zhu, Harry C Blair, Lisa J Robinson, Jameel Iqbal, Li Sun, Mone Zaidi.   

Abstract

In nonneuronopathic type 1 Gaucher disease (GD1), mutations in the glucocerebrosidase gene (GBA1) gene result in glucocerebrosidase deficiency and the accumulation of its substrate, glucocerebroside (GL-1), in the lysosomes of mononuclear phagocytes. This prevailing macrophage-centric view, however, does not explain emerging aspects of the disease, including malignancy, autoimmune disease, Parkinson disease, and osteoporosis. We conditionally deleted the GBA1 gene in hematopoietic and mesenchymal cell lineages using an Mx1 promoter. Although this mouse fully recapitulated human GD1, cytokine measurements, microarray analysis, and cellular immunophenotyping together revealed widespread dysfunction not only of macrophages, but also of thymic T cells, dendritic cells, and osteoblasts. The severe osteoporosis was caused by a defect in osteoblastic bone formation arising from an inhibitory effect of the accumulated lipids LysoGL-1 and GL-1 on protein kinase C. This study provides direct evidence for the involvement in GD1 of multiple cell lineages, suggesting that cells other than macrophages may be worthwhile therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962279      PMCID: PMC2984187          DOI: 10.1073/pnas.1003308107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses.

Authors:  T M Cox
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

2.  A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

Authors:  Elena Lukina; Nora Watman; Elsa Avila Arreguin; Maryam Banikazemi; Marta Dragosky; Marcelo Iastrebner; Hanna Rosenbaum; Mici Phillips; Gregory M Pastores; Daniel I Rosenthal; Mathilde Kaper; Tejdip Singh; Ana Cristina Puga; Peter L Bonate; M Judith Peterschmitt
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

3.  Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.

Authors:  Hiroki Mizukami; Yide Mi; Ryuichi Wada; Mari Kono; Tadashi Yamashita; Yujing Liu; Norbert Werth; Roger Sandhoff; Konrad Sandhoff; Richard L Proia
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

4.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 5.  The pathogenesis of glycosphingolipid storage disorders.

Authors:  Luba Ginzburg; Yaacov Kacher; Anthony H Futerman
Journal:  Semin Cell Dev Biol       Date:  2004-08       Impact factor: 7.727

Review 6.  Gaucher disease: complexity in a "simple" disorder.

Authors:  Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

7.  Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy.

Authors:  Pramod K Mistry; Sandra Sirrs; Alicia Chan; Mark R Pritzker; Thomas P Duffy; Marie E Grace; David P Meeker; Martin E Goldman
Journal:  Mol Genet Metab       Date:  2002 Sep-Oct       Impact factor: 4.797

8.  Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.

Authors:  Richard J Wenstrup; Laurie Bailey; Gregory A Grabowski; Jay Moskovitz; Alan E Oestreich; Wei Wu; Shumei Sun
Journal:  Blood       Date:  2004-03-09       Impact factor: 22.113

Review 9.  Functions of sphingolipids and sphingolipid breakdown products in cellular regulation.

Authors:  Y A Hannun; R M Bell
Journal:  Science       Date:  1989-01-27       Impact factor: 47.728

10.  Identification of a molecular target of psychosine and its role in globoid cell formation.

Authors:  D S Im; C E Heise; T Nguyen; B F O'Dowd; K R Lynch
Journal:  J Cell Biol       Date:  2001-04-16       Impact factor: 10.539

View more
  91 in total

1.  Gaucher disease gene GBA functions in immune regulation.

Authors:  Jun Liu; Stephanie Halene; Mei Yang; Jameel Iqbal; Ruhua Yang; Wajahat Z Mehal; Wei-Lien Chuang; Dhanpat Jain; Tony Yuen; Li Sun; Mone Zaidi; Pramod K Mistry
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.

Authors:  Melissa Wasserstein; James Godbold; Margaret M McGovern
Journal:  J Inherit Metab Dis       Date:  2012-06-21       Impact factor: 4.982

3.  Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton.

Authors:  Graziana Colaianni; Li Sun; Adriana Di Benedetto; Roberto Tamma; Ling-Ling Zhu; Jay Cao; Maria Grano; Tony Yuen; Sylvia Colucci; Concetta Cuscito; Lucia Mancini; Jianhua Li; Katsuhiko Nishimori; Itai Bab; Heon-Jin Lee; Jameel Iqbal; W Scott Young; Clifford Rosen; Alberta Zallone; Mone Zaidi
Journal:  J Biol Chem       Date:  2012-07-02       Impact factor: 5.157

Review 4.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

Review 5.  A Next Generation Multiscale View of Inborn Errors of Metabolism.

Authors:  Carmen A Argmann; Sander M Houten; Jun Zhu; Eric E Schadt
Journal:  Cell Metab       Date:  2015-12-17       Impact factor: 27.287

6.  Mechanisms of Gaucher disease pathogenesis.

Authors:  Simon Wheeler; Dan John Sillence
Journal:  Ann Transl Med       Date:  2015-05

7.  Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Authors:  Raquel Romero; Arvind Ramanathan; Tony Yuen; Debsindhu Bhowmik; Mehr Mathew; Lubna Bashir Munshi; Seher Javaid; Madison Bloch; Daria Lizneva; Alina Rahimova; Ayesha Khan; Charit Taneja; Se-Min Kim; Li Sun; Maria I New; Shozeb Haider; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

8.  Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease.

Authors:  Yuliya Afinogenova; Jiapeng Ruan; Ruhua Yang; Nathaniel Kleytman; Gregory Pastores; Andrew Lischuk; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2019-07-23       Impact factor: 4.797

9.  Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation.

Authors:  Shiny Nair; Chandra Sekhar Boddupalli; Rakesh Verma; Jun Liu; Ruhua Yang; Gregory M Pastores; Pramod K Mistry; Madhav V Dhodapkar
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

10.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.